Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Mid 2018 – Recap of Warning Letters, Import Alerts and Non-Compliances
In our mid-2018 compliance review, we look at inspection challenges
faced by companies across the w
Emcure’s US CEO ‘looted millions’, fixed prices with Mylan, Teva and others
As 2016 draws to a close, we look at some recent cases of (alleged) drug
price-fixing and examines i
Will data integrity concerns on clinical trials done at GVK Biosciences go beyond Europe?
Over
700 commonly used generic medicines were
recommended for suspension by the European Medic
